Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA

Figure 3

The dose-dependent kinetics of QR-si510 siRNA nanoplex on HIV-1-infected THP-1 cells. THP-1 monocytic cultures were treated with lipofectamine transfected scrambled siRNA (5–100 nM), Lipofectamine transfected si510 HIV-1 siRNA (5–100 nM) and the QR-si510 siRNA (5–100 nM) nanoplex for a 48 hr time period and the p24 production was measured in the supernatants at the end of the incubation period using a commercially available p24 ELISA kit. Untransfected HIV-1-infected THP-1 and the non-HIV-1-infected THP-1 cells (nonvirus control) were the experimental controls. The lipofectamine was used as per manufacturer’s protocol. Our results show that 10 nM of the QR-si510 HIV-1siRNA nanoplex was optimal in achieving almost 85% suppression of viral replication. The results shown are mean ± SD of 3 separate experiments.